Crux pumps in $8M to prevent embolisms
Crux Biomedical has raised $8 million in second-round funding to cover its debt and finalize clinical trials on its device used to remove blood clots and air bubbles from the bloodstream. The Menlo Park, Calif. firm initiated testing in 2006 in Paraguay and implanted its first filter in the U.S. in October 2007. If used correctly, the device could prevent life-threatening pulmonary embolisms, the company says.
The recent funding came from Alloy Ventures and private investor Thomas Fogarty, who has a history of backing medical device makers. It should be enough to pay off Crux’s debt, totaling about $1.2 million. The company raised a first round of $3.85 million in 2006.
Next Story: mEgo snags $2.5M for avatar-based widgets
Previous Story: TPI Composites raises $20M for wind turbine blades
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.